A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Trial Profile

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Jan 2018 Results (n=36; data cuf off June 30, 2017) assessing efficacy and safety of ABT 199 in patients with relapsed or refractory chronic lymphocytic leukemia after B-cell receptor signaling pathway inhibitors (BCR PI) treatment, were published in the Blood.
    • 12 Dec 2017 Results of an analysis identifying Richters transformation using PET-CT in screened patients from this study (n=167), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=28; data cut off 31 Jan 2017) assessing outcomes with Venetoclax monotherapy for a subset of patients who received more than one prior BCRi presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top